AAP
IMMX icon

Arax Advisory Partners’s Immix Biopharma IMMX Stock Holding History

Arax Advisory Partners’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-34
Closed -$71 – 4296
2025
Q3 		$71 Buy
+34
New +$82 ﹤0.01% 3520

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Arax Advisory Partners's IMMX Position: Q4 2025 in Review

Arax Advisory Partners sold out of Immix Biopharma (IMMX) in Q4 2025, closing a stake of 34 shares — an estimated $71 sold.

Arax Advisory Partners first reported a position in IMMX in Q3 2025 and held it in 1 quarter. The position peaked at $71 in Q3 2025. 67 funds tracked by Wall St. Rank hold IMMX as of Q4 2025.

  • Arax Advisory Partners reported no remaining Immix Biopharma position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 34 Immix Biopharma shares in Q4 2025, an estimated $71.
  • Arax Advisory Partners first reported a position in Immix Biopharma in Q3 2025 and held it in 1 quarter.
  • Arax Advisory Partners's Immix Biopharma position peaked at $71 in Q3 2025.
  • 67 funds tracked by Wall St. Rank held Immix Biopharma as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.